ORCiD numbers: 0000-0001-7743-7786 (E. A. Southmayd).
T he time of adolescence and young adulthood presents a key window for optimizing bone mass in women, as lifetime peak bone mass is accrued by the mid20s to upper 20s (1) (2) (3) . Conditions or lifestyle behaviors that are detrimental to bone may be most harmful during this vulnerable time period. Exercise-associated menstrual disturbances, including amenorrhea, represent one such condition that may impair bone health in young women. Indeed, menstrual disturbances represent one of the three components that comprise the condition known as the female athlete triad (Triad) (4) . In the Triad model, low energy availability (EA) is the causal factor that leads to suppression of reproductive hormones (manifesting as menstrual disturbances) and compromised bone mineral density (BMD).
In a 2014 systematic review, Gibbs et al. (5) determined that up to 60% of exercising girls and women may present with at least one component of the Triad, demonstrating the magnitude and widespread prevalence of this condition. In women with the Triad, bone health is the clinical outcome of urgent concern, as it is not certain that BMD can be fully recovered after chronic energy and/or estrogen deficiency (6) (7) (8) . Aside from measuring BMD, bone health can be evaluated by assessing bone turnover, the dynamic process of cyclic resorption and formation. Although bone-loading physical activity is expected to upregulate bone turnover and result in a net increase in bone formation in accordance with the mechanostat theory (9), energy and estrogen deficiency associated with the Triad may dysregulate bone formation and resorption (10) (11) (12) (13) (14) and outweigh the osteogenic benefits of exercise (15) . When used in mathematic models of bone turnover, serum markers of bone formation and resorption describe the relative coupling of bone formation and resorption and the rate of bone turnover, an additional characteristic that may impact BMD or fracture risk (16) (17) (18) (19) (20) . One such approach, described by Bieglmayer and Kudlacek (16) , utilizes multiple of median (MoM) scores to represent an individual's bone marker concentration relative to an average from a reference group to reflect deviation from the norm. The ratio of MoM scores of formation to resorption defines bone balance, and the magnitude of formation and resorption scores defines bone turnover rate (BTR). The values obtained from the MoM approach can be graphically displayed in a "bone turnover plot" to visually depict group differences in bone turnover dynamics or to track an individual's bone turnover response across time during an intervention or treatment regimen.
In exercising women, varying states of energy and estrogen will likely influence bone turnover dynamics through changes in the balance of bone formation and resorption. Thus, the aims of the current study were (i) to assess the independent and combined roles of energy status and estrogen (menstrual) status on bone turnover dynamics (indices of bone formation, resorption, balance, and turnover rate) in exercising women using the MoM mathematical algorithm approach described (16) , and (ii) to determine variables predictive of bone formation, resorption, balance, and turnover rate indices in exercising women. It was hypothesized that energy deficiency would be related to a suppressed bone formation index, decreased bone balance, and a lower BTR, and estrogen deficiency would be related to an increased bone resorption index and decreased bone balance that favors resorption over formation.
Methods

Study design
This study was a cross-sectional secondary analysis based on a posteriori hypotheses. Premenopausal exercising women (n 5 109) represented a full spectrum of energy and estrogen statuses, ranging from replete to deficient. The data set comprised two studies: (1) baseline data from a 12-month randomized controlled trial investigating the effect of increased caloric intake on menstrual cyclicity and bone health in exercising women with menstrual disturbances (REFUEL, n 5 90), and (ii) data from a cross-sectional observational study evaluating estimated bone strength in exercising women along a spectrum of menstrual function ranging from amenorrheic to eumenorrheic [Active Women's Study (AWS), n 5 19] . Inclusion criteria for both studies were similar enough to warrant pooling of the data, and small differences that did exist between inclusion criteria were not of a nature that would introduce bias to the current analyses. Differences in the inclusion criteria were: (i) age range: REFUEL, 18 to 35 years; AWS, 18 to 30 years; (ii) body mass index (BMI): REFUEL, 16 to 25 kg/m 2 ; AWS, 16 to 29.9 kg/m 2 ; and (iii) weight stability: REFUEL, weight stable within 2 kg for 6 months; AWS, no requirement. Inclusion criteria encompassing both studies are detailed in the "Participants" section below. To be included in the analysis, the women had to have recorded a minimum of 120 minutes of physical activity on a 7-day exercise log during study participation. Furthermore, women were excluded from the data set when they did not have measurements needed to assess the main outcomes of this study, including serum measurements of procollagen type I N-terminal propeptide (P1NP; bone formation) and serum C-terminal telopeptide (sCTx; bone resorption), or data to determine the main independent grouping variables of energy status [total triiodothyronine (TT 3 ) concentration measurement) and estrogen status (menstrual history for $6 months).
Energy status was operationally defined based on a median split of TT 3 measurements for the entire sample of participants. The median TT 3 concentration (84.95 ng/dL) emerged as a cutpoint, evenly and organically dividing the sample into those with higher and lower TT 3 concentrations. Women with a TT 3 concentration $84.95 ng/dL were considered energy replete (EnR, n 5 55), and those with a TT 3 concentration ,84.95 ng/dL were considered energy deficient (EnD, n 5 54). As a point of reference, the Centers for Disease Control and Preventionreported clinical range for normal TT 3 is 80 to 200 ng/dL (21) . The use of TT 3 concentration as an indicator of energy status was made in light of the eloquent laboratory experiments of Loucks et al. (10, (22) (23) (24) (25) in which laboratory controlled reduction of EA via dietary restriction relative to energy expenditure induced low TT 3 syndrome, as well as a host of other metabolic perturbations. Field studies of exercising women have corroborated the relationship between TT 3 concentrations and energy (26) (27) (28) (29) , supporting the use of TT 3 concentration in our operational definition of energy status.
Estrogen status was based on self-reported history of menses in the past 3 and 12 months and confirmed with urinary measurements of metabolites of estrogen [estrone-1-glucuronide (E1G)] and progesterone [pregnanediol glucuronide (PdG)]. Women were defined as estrogen deficient (E 2 D, n 5 50) or estrogen replete (E 2 R, n 5 59) (see "Assessment of menstrual function and estrogen status" below). Further subdivision based on energy and estrogen status resulted in four distinct groups: EnD 1 E 2 D (n 5 32), EnD 1 E 2 R (n 5 22), EnR 1 E 2 D (n 5 18), and EnR 1 E 2 R (n 5 37) (Fig. 1) .
Both studies from which data were pooled were approved by the Biomedical Institutional Review Board(s) of the university where the studies took place: the University of Toronto (RE-FUEL) and/or the Pennsylvania State University (REFUEL and AWS). Before any data were collected, the study volunteers were informed of the purpose, procedures, and potential risks of study participation and written informed consent was obtained.
Participants
Participants for both studies were recruited by fliers posted on the campuses and surrounding communities where the studies were conducted, listserv e-mail announcements, Web site postings, and classroom handouts. Inclusion criteria were (i) age 18 to 35 years, (ii) BMI of 16 to 29.9 kg/m 2 , (iii) nonsmoking, (iv) in generally good health, (v) free of metabolic disease or disease known to alter bone health, (vi) not taking hormonal medication, including hormonal contraception, for $6 months, (vii) not pregnant or lactating, (viii) no known bone disease or disorder, (ix) no history of hysterectomy or oophorectomy, and (x) participating in at least 120 minutes of purposeful physical activity per week.
Study procedures
Questionnaires
Upon study enrollment, participants completed a basic health history questionnaire to provide information about demographics, eating disorder history, menstrual cycle history, physical activity history, bone health and stress fracture history, and medication and supplement use.
Anthropometric measurements
Height was measured using a wall-mounted stadiometer to nearest 0.1 cm. Body weight was measured on a digital scale to the nearest 0.01 kg. BMI was calculated as the ratio of body weight to height (kg/m 2 ). 
BMD and body composition
Aerobic fitness
Aerobic fitness was assessed as peak oxygen consumption (VO 2 ) measured during a progressive treadmill test using breathby-breath indirect calorimetry (V max metabolic cart; SensorMedics, Yorba Linda, CA) [methods are published in Ref. (30) ]. Briefly, after a 3-to 5-minute walk/jog warm-up, participants started running at a comfortable self-selected speed with no incline. For the first 6 minutes of the test, the incline was increased 2% every 2 minutes. Thereafter, the incline was increased 1% every 1 minute. The test continued until volitional fatigue was reached, indicated by a participant rating of perceived exertion of $18 on a 20-point scale, age-predicted maximal heart rate was achieved (220 2 age), a plateau in VO 2 despite increased workload was observed, and/or the participant requested that the test be terminated. Maximum VO 2 recorded during the test was determined to be the participant's peak VO 2 (kg of O 2 /kg of body weight/min).
Resting energy expenditure
Resting energy expenditure (REE), measured to corroborate energy status, was assessed using indirect calorimetry in a ventilated hood system (V max series; SensorMedics). To assess REE, participants arrived at the laboratory between 0600 and 0900 hours in a 12-hour fasted state, having refrained from caffeine, alcohol, and vigorous exercise for $24 hours. Upon arriving at the laboratory, participants laid supine in a dimly lit room for $30 minutes to achieve a relaxed state, after which time a clear hood attached to a metabolic cart was lowered over the head. Carbon dioxide production (VCO 2 ; mL/min) and VO 2 (mL/min) were subsequently assessed for $30 minutes in 30- 
Blood collection
Blood samples were collected via venipuncture to assess metabolic hormones associated with energy status (TT 3 , leptin) and bone turnover markers (P1NP and sCTx) in serum. Blood collection occurred immediately following the REE assessment. Thus, participants were in a 12-hour fasted state and had refrained from caffeine, alcohol, and vigorous physical activity for $24 hours. All blood sample collections were standardized to occur before 1000 hours to minimize the effects of diurnal variation in measurements. Following blood collection, samples were allowed to clot for $30 minutes at room temperature and were subsequently centrifuged for 15 minutes at 4°C and 3000 rpm. Serum was then transferred from the vacutainers into microtubules and stored at 280°C until analyses. For participants in the REFUEL study, blood samples obtained during the baseline phase of the study and the first week of a subsequent nutritional intervention were pooled for analyses representative of the baseline. For the participants in the AWS, only one blood sample was obtained.
Metabolic hormone assays
Serum TT 3 was analyzed using a competitive immunoassay (Siemens Healthcare Diagnostics, Tarrytown, NY) on a chemiluminescence immunoassay analyzer (Immulite; Diagnostic Products Corporation, Los Angeles, CA). Sensitivity for the TT 3 assay was 0.54 nmol/L (35 ng/dL). The intra-assay and interassay CVs were 10.3% and 13.3%, respectively. Serum leptin was measured using a solid-phase sandwich ELISA for total leptin (Millipore, St. Charles, MO). All samples were measured in duplicate, and the content of leptin in samples was calculated from a standard curve generated in each assay with recombinant human leptin. The assay was sensitive to leptin concentrations $0.125 ng/mL. Intra-assay and interassay CVs were 4.9% and 8.6%, respectively.
Bone turnover marker assays PINP was measured using an RIA (Orion Diagnostica, Oslo, Finland). The sensitivity of the PINP assay was 2 mg/L. The intra-assay and interassay CVs were 10% and 10%, respectively. sCTx was measured using an ELISA. The sensitivity of the sCTx assay was 0.02 ng/mL. The intra-assay and interassay CVs were 3% and 10%, respectively.
Urine collection
Participants collected daily first morning void urine samples for either one 28-day monitoring period (if amenorrheic) or one complete menstrual cycle (if menstruating) for the assessment of urinary metabolites of the reproductive hormones estrogen (E1G), progesterone (PdG), and luteinizing hormone (LH). Samples were collected in specimen containers and kept frozen until participants returned the samples to the laboratory. The samples were then thawed and transferred into microtubules, specific gravity was measured, and the samples were stored at 220°C until analysis.
All daily urine samples were assayed for E1G and PdG using microtiter plate competitive enzyme immunoassays. The E1G (R522-2) and PdG (R13904) assays use a polyclonal capture antibody supplied by the Coralie Munro University of California (Davis, CA). The interassay CVs for high and low internal controls for the E1G assay were 14.7% and 13.1%, respectively, and the PdG intra-assay and interassay variability were determined in-house as 15.68% and 17.7%, respectively. Urinary LH was measured using a Coat-a-Count immunoradiometric assay (Siemens Healthcare Diagnostics, Deerfield, IL). The intra-assay and interassay CVs were 1.6% and 7.1%, respectively. To account for hydration status, specific gravity of each urine sample was determined using a hand refractometer (NSG Precision Cells, Farmingdale, NY) (32) . To compare estrogen and progesterone exposure among participants, Kaleidagraph (software version 4.1.1; Synergy Software, Reading, PA) was used to calculate area under the curve (AUC) for E1G and PdG across the entire menstrual cycle or 28-day monitoring period. Mean E1G and PdG concentrations were also calculated for each menstrual cycle or 28-day monitoring period to further assess estrogen and progesterone exposure. LH measurements were used in conjunction with E1G and PdG concentrations and patterns across the cycle to qualitatively assess the presence or absence of ovulation during the menstrual cycle and determine whether subclinical menstrual disturbances were present (see "Assessment of menstrual function and estrogen status" below).
Assessment of menstrual function and estrogen status
As described above, estrogen status was defined based on self-reported history of menses in the last 3 and 12 months and corroborated with daily measurements of urinary metabolites of reproductive hormones for one 28-day monitoring period (if amenorrheic) or one compete menstrual cycle (if menstruating). Women were considered amenorrheic when they reported no menses in the past 3 months and had an E1G/PdG profile of suppressed reproductive hormones during a 28-day monitoring period. Women were considered oligomenorrheic when they reported at least one menses in the past 3 months but experienced long and inconsistent menstrual cycles, as well as a menstrual cycle that was .36 days and ,90 days in length when urinary hormone metabolites were assessed. Women were considered eumenorrheic when they reported two to three menses in the past 3 months and experienced a cycle that was ,36 days in length when urinary hormone metabolites were assessed for a complete menstrual cycle. Women who were eumenorrheic or oligomenorrheic but reported six or more menstrual cycles in the past 12 months were considered E 2 R (n 5 59). Women who were amenorrheic or oligomenorrheic but reported fewer than six menstrual cycles in the past 12 months were considered E 2 D (n 5 50).
Menstrual cycles were also assessed for quality based on the patterns and concentrations of E1G, PdG, and LH across the monitoring period/menstrual cycle. Specifically, evidence of ovulation based on follicular phase E1G and LH activity and luteal phase PdG activity and the length and adequacy of the luteal phase (when ovulation occurred) were assessed. In amenorrheic women, E1G and PdG concentrations were suppressed throughout the monitoring period with few day-to-day fluctuations. In eumenorrheic and oligomenorrheic women, ovulation was determined to have occurred when the following criteria were met: an LH surge of at least 25 mIU/mL occurring the day of or shortly after a mid-cycle E1G peak of at least 25 ng/mL and followed by a rise in PdG to at least 2.5 mg/mL. When the aforementioned criteria were not met in menstruating women, the cycle was classified as anovulatory. In ovulatory cycles, the day of the LH surge was used to delineate the follicular phase from the luteal phase. Luteal phase defects were defined as either a short luteal phase (,10 days between the day of LH surge and the onset of subsequent menses), an inadequate luteal phase (PdG .2.5 mg/mL but ,5 mg/mL during the luteal phase), or a short and inadequate luteal phase (satisfied both criteria) (14, 33-36). All oligomenorrheic cycles, whether ovulatory or anovulatory, were regarded as one category.
LH data were not available for eight eumenorrheic participants, but PdG concentrations of at least 2.5 mg/mL in the second half of the cycle were observed, indicating that ovulation was likely; those cycles were classified as eumenorrheicevidence of luteal activity (33) . For five oligomenorrheic participants, the urine collection was incomplete and did not allow for specific cycle characterization, and those cycles were classified as "oligomenorrheic-indeterminate." One (n 5 1) participant who reported 3, 6, 9, and 12 menses in the past 3, 6, 9, and 12 months, respectively, met the criteria for E 2 R and eumenorrheic, but did not collect a full cycle of urine; this participant's cycle type was not classified, but the participant was included in the main analyses (i.e., bone turnover outcomes).
Assessment of bone turnover dynamics
The bone formation index [MoM score for formation (MoMf)], bone resorption index [MoM score for resorption (MoMr)], bone balance, and BTR were calculated using algorithms incorporating serum concentrations of bone turnover markers, P1NP and sCTx (16) . MoMf and MoMr were calculated [Eq. (1)]. The median P1NP and sCTx concentrations from a database of n 5 36 healthy, eumenorrheic, ovulatory, exercising women (age 23 6 0.8 years; range, 18 to 35 years) in our laboratory was used as the reference to calculate MoMf and MoMr, as denoted by the subscript "OV" in Eq. (1) (2)], such that a value of 1 is indicative of net bone balance, a value .1 is indicative of net bone formation, and a value ,1 is indicative of net bone resorption.
Equation 2
BB ¼ MoMf MoMr BTR [Eq. (3)] was calculated based on the relative magnitudes of bone formation and resorption, such that increased formation and/or resorption would result in a faster BTR. If formation and resorption were balanced and equal to that of the ovulatory reference group, the BTR would be equal to ffiffiffi 2 p .
Equation 3
BTR ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi
Bone turnover dynamics were graphed on a bone turnover plot (example in Fig. 2 ) based on the values obtained in Eqs.
(1)-(3). The bone formation index (MoMf) was on the y-axis and the bone resorption index (MoMr) was on the x-axis, such that the slope of the line from the origin (0,0) to point a(MoMr, MoMf) is equal to bone balance and the length of the vector from the origin (0,0) to point a(MoMr, MoMf) is equal to BTR.
Statistical analyses
Before any statistical analyses were performed, assumptions specific to the statistical test of interest were evaluated. When assessing group differences, data were screened for normal distribution using the Shapiro-Wilk statistic and for homogeneity of variance among the groups using the Levene statistic. With respect to bone turnover markers, which were the main dependent variables of interest, participants with values that were considered outliers ($3 SDs above the average) were excluded.
Two-way ANOVA was used to assess the main effects of energy status and estrogen status and the interactive effects of energy and estrogen status on demographic information, body composition, metabolic hormones, bone turnover markers, BMD, E1G and PdG concentrations, REE, and bone turnover dynamics (bone formation index, bone resorption index, bone balance, and BTR). All bone turnover variables displayed nonnormal distributions and were natural log transformed for analyses. Reproductive hormone concentrations displayed nonnormal distributions; the E1G AUC and mean were transformed using y 5 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi x 1 0:5 p , and the PdG AUC and mean were natural log transformed for analyses. Leptin concentrations were not normally distributed and violated the assumption of homogeneity of variance and were square root transformed for analyses. When significant interactions were present between energy and estrogen status, a simple effects analysis was performed to assess at which levels of each independent variable significant differences in the outcome measure were observed. That is, differences between EnD and EnR women were assessed within the E 2 D group (EnD 1 E 2 D vs EnR 1 E 2 D) and within the E 2 R group (EnD 1 E 2 R vs EnR 1 E 2 R); differences between E 2 D and E 2 R women were assessed within the EnD group (EnD 1 E 2 D vs EnD 1 E 2 R) and within the EnR group (EnR 1 E 2 D vs EnR 1 E 2 R). For the pairwise comparisons, P values were Bonferonni adjusted to account for multiple comparisons. To assess factors that best predicted bone turnover dynamics, Spearman correlation analyses were first performed. The factors considered as predictors of bone turnover dynamics can be categorized as general demographics (age, age of menarche, gynecological age, height, weight, BMI), body composition measures (fat mass, LBM, FFM, body fat percentage), reproductive hormone metabolite concentrations (E1G and PdG AUC and mean concentration), REE (REE/kg LBM/d), and metabolic hormone concentrations (TT 3 , leptin). Variables that displayed significant correlations with bone turnover dynamic measurements were carried forward into simple linear regression analyses to determine significant independent predictors of bone turnover dynamics. Next, multivariable regression using the "enter" method was used to assess collinearity between variables that were significant independent predictors of bone turnover dynamics, with the intent of determining which variables should be carried forward into stepwise hierarchical regression modeling. Variables that were deemed collinear by evaluating variance inflation factors were not carried forward together into stepwise hierarchical regression (i.e., age and gynecological age, fat mass and percent body fat, weight, and BMI). In these instances, the predictor that accounted for a greater proportion of variance in the dependent variable in the simple linear regression analyses (i.e., larger R 2 ) was entered into the stepwise hierarchical regression models to create multivariable prediction models for bone turnover dynamics. Specifically, for each bone turnover variable [bone formation index (MoMf), bone resorption index (MoMr), bone balance, and BTR], stepwise hierarchical regression was performed such that in the first block, variables that were deemed "clinically available" were eligible for entry into the model, including age, age of menarche, gynecological age, height, weight, and BMI. Body composition variables (fat mass, LBM, FFM, and percent body fat) that may be available in some clinical settings were eligible for entry in the second block. Finally, additional variables that may be available in certain circumstances in a clinical or research setting and may yield mechanistic information were eligible for entry into the final block of the model, including REE, TT 3 and leptin concentrations, and E1G and PdG AUCs and mean concentrations. With this stepwise hierarchical regression technique, the goal was to provide predictive models of bone turnover that could be of use in clinical and research settings with access to a varied range of measurements.
Bone marker data from a previous publication from our laboratory (14) were used to calculate the expected effect size to determine an adequate sample size. Although no previous literature has assessed bone balance and BTR in premenopausal women using the algorithms described herein, De Souza et al. (14) assessed bone formation (P1NP) and resorption (uCTx) markers in a sample of exercising women similar to those currently being studied. To have 80% power to detect an expected effect size of 1.05 for P1NP and 0.86 for uCTx (comparing the EnR and E 2 R women to EnD and E 2 D women), we calculated that sample sizes of n 5 32 and n 5 46 women, respectively, were necessary. Thus, with our sample size of n 5 109 women, we concluded we had adequate power to detect differences in bone turnover based on energy and estrogen status should differences exist. For all statistical analyses, significance level was set to a 5 0.05 unless otherwise specified. All data were analyzed using SPSS for Windows statistical software package (version 24.0; SPSS, Chicago, IL). All tables and figures contain raw, nontransformed values and are presented as mean 6 SEM.
Results
Subject characteristics
Subject characteristics are displayed in Table 1 . The sample consisted of n 5 109 exercising women who were, on average, 22 years old, weighed 58 kg, and had 26% body fat. The women were physically active, evidenced by an average reported exercise volume of 5.5 hours per week (range, 120 to 1305 minutes per week) and corroborated by an average peak VO 2 of 48.6 mL O 2 /kg/min (range, 30 to 71.4 mL O 2 /kg/min). There was a significant main effect of energy status on gynecological age (calculated as age minus age of menarche) such that compared with EnR women, EnD women had an older gynecological age (9.4 6 0.6 vs 8.6 6 0.6 years). Additionally, there was a main effect of energy status on peak VO 2 , such that EnD women had a significantly greater peak VO 2 compared with EnR women (50.7 6 1.3 vs 46.3 6 1.3 mL O 2 /kg/min). There was a significant main effect of estrogen status on age, BMI, age of menarche, and gynecological age such that compared with E 2 R women, E 2 D women were younger (21.3 6 0.4 vs 22.7 6 0.6 years), had a lower BMI (20.7 6 0.3 vs 21.8 6 0.3 kg/m 2 ), reported an older age of menarche (13.8 6 0.2 vs 12.6 6 0.2 years), and therefore were of younger gynecological age (7.6 6 0.5 vs 10.2 6 0.6 years). There were significant interaction effects of energy and estrogen status on body fat percentage, fat mass, and leptin. Simple effects analyses reveled body fat percentage and fat mass were significantly lower in the
With respect to absolute concentrations of the bone turnover markers (P1NP and sCTx), there was an interaction effect of energy and estrogen status on P1NP (P 5 0.046), and simple effects analyses revealed that P1NP was significantly lower in the EnD 1 E 2 D women compared with the EnR 1 E 2 D women (53.6 6 3.2 vs 77.9 6 7.3 mg/L, P 5 0.002). There was a significant main effect of energy status on sCTx, such that sCTx was significantly lower in the EnD women compared with the EnR women (0.65 6 0.05 vs 0.76 6 0.4 ng/mL, P 5 0.019).
Energy status
The median TT 3 concentration of the full sample was 84.95 ng/dL (range, 45.05 to 143.50 ng/dL), which is 
Estrogen status
Two-way ANOVA analyses revealed significant main effects of estrogen status on E1G mean and PdG AUC and mean concentrations, which were all significantly lower in the E 2 D women compared with the E 2 R women (P , 0.001), confirming the appropriate definition of the groups as "estrogen replete" and "estrogen deficient." There was a significant interaction effect of energy and estrogen status for E1G AUC (P 5 0.020), revealing a difference between the EnD 1 E 2 R and EnD 1 E 2 D women as depicted in Table 1 . No significant differences in urinary metabolites of estrogen or progesterone were observed between the EnR and EnD women collapsed across estrogen status.
Menstrual cycle types were classified according to E1G and PdG concentrations and patterns across the monitoring period/menstrual cycle (Fig. 3) . Most participants in the E 2 D groups (EnD 1 E 2 D and EnR 1 E 2 D) were amenorrheic (88% and 72%, respectively), whereas most participants' cycles in the E 2 R groups (EnD 1 E 2 R and EnR 1 E 2 R) were eumenorrheic with confirmed ovulation or evidence of luteal activity (88% and 75%, respectively). Despite the classification as "estrogen replete," many women experienced subclinical menstrual disturbances. Specifically, 23%, 9%, and 23% of the women in the EnD 1 E 2 R group and 14%, 11%, and 17% of the women in the EnR 1 E 2 R group exhibited oligomenorrhea, anovulation, or a luteal phase defect, respectively.
Bone mineral density
Average BMD and Z-score for the total body, lumbar spine, femoral neck, and total hip are displayed in Table 1 . Two-way ANOVA demonstrated a significant main effect of estrogen on total body and lumbar spine BMD and Z-score, whereby BMD and Z-scores were Figure 3 . Distribution of menstrual cycle types among the subgroups. The women in the EnD 1 E 2 D group had the largest proportion of amenorrheic women (88%) whereas the EnR 1 E 2 R group had the largest proportion of eumenorrheic ovulatory women (47%). Subclinical menstrual disturbances (luteal phase defects, anovulation, oligomenorrhea) were observed in all four subgroups. Amen, amenorrheic; Anov, anovulatory; Eumen-LA, eumenorrheic, evidence of luteal activity; Eumen-Ov, eumenorrheic ovulatory; LPD, luteal phase defect; Oligo, oligomenorrheic; Oligo-Ind, oligomenorrheic indeterminate.
lower in E 2 D women compared with E 2 R women (E 2 D total body BMD 5 1.106 6 0.103, Z-score 5 0.42261.057; E 2 R total body BMD 5 1.159 6 0.089, Z-score 5 0.979 6 0.831; E 2 D L1 to L4 BMD 5 1.096 6 0.137, Z-score 5 20.537 6 1.079; E 2 R L1 to L4 BMD 5 1.209 6 0.121, Z-score 5 0.427 6 0.969, P , 0.010). There were no main or interaction effects of energy or estrogen at the femoral neck or total hip.
Bone turnover dynamics
The median concentrations of P1NP and sCTx in the reference database of healthy, eumenorrheic, ovulatory control women that were used to calculate the indices of bone formation and resorption were 54.285 mg/L and 0.643 ng/mL, respectively. Figure 4 displays the bone turnover dynamic measurements among the four distinct energy and estrogen groups. Notably, on average, all groups demonstrated bone formation index, bone resorption index, and bone balance values .1, and BTR .1.41 (i.e., ffiffiffi 2 p ), indicating that bone turnover was elevated in our sample compared with the in-house database of healthy, eumenorrheic, ovulatory women that was used as a reference population.
Two-way ANOVA (Table 2 ) revealed significant interaction effects of energy and estrogen status on the bone formation index (MoMf, P 5 0.046) and BTR (P 5 0.045). Simple effects analyses revealed that among E 2 D women, those that were EnD had a lower bone formation index and a slower rate of bone turnover than did the women who were EnR (i.e., EnD 1 E 2 D vs EnR 1 E 2 D, P , 0.002). The bone formation index and BTR did not differ in the E 2 R women as a function of energy status. A main effect of energy status on the bone resorption index was observed as well, whereby EnD women had a significantly lower bone resorption index than did the EnR women (1.01 6 0.04 vs 1.17 6 0.06). There were no significant main or interaction effects of energy and estrogen status on bone balance, and there were no main effects of estrogen status on any of the bone turnover variables. Figure 5 depicts bone turnover dynamics among the four groups on a composite bone turnover plot. For each group, the bone resorption index was plotted (x-axis) against the bone formation index (y-axis), and the length of the line indicates BTR. The bone turnover plot demonstrates that the EnD 1 E 2 R group had the greatest bone balance (greatest slope). It is also apparent from the length of the lines that BTR was greatest in the EnR 1 E 2 D women, who differed significantly from the EnD 1 E 2 D women (P 5 0.004).
Predictors of bone turnover
Spearman correlation analyses were performed to assess significant (P , 0.10) associations between bone turnover dynamics and all other measurements (Table 3) . Significantly associated variables were assessed as predictors of bone turnover dynamics via simple linear regression analyses (Table 3) . Age, weight, BMI, gynecological age, body fat percentage, fat mass, and TT 3 and leptin concentrations were deemed significant independent predictors of the bone formation index (P # 0.040). Age, gynecological age, and TT 3 concentrations were significant independent predictors of the bone resorption index (P # 0.013). BMI was the only variable identified as a significant independent predictor of bone balance (P 5 0.036). Finally, age, gynecological age, fat mass, and TT 3 concentrations were independent predictors of the BTR (P # 0.034). E1G and PdG AUCs and mean concentrations were not significant independent predictors of any bone turnover dynamic variables. Stepwise hierarchical regression analyses were used to determine significant multivariable models of bone turnover dynamics. The models that emerged as significant for each dependent variable are depicted in Table 4 . Adjusted R 2 values are presented to correct for different numbers of predictor variables in the models. R 2 change is calculated based on unadjusted R 2 . Taking into account the need to avoid multicollinearity, the following variables were tested in the model for the bone formation index: block 1, weight, gynecological age; block 2, fat mass; block 3, TT 3 , leptin. The models that emerged indicated that gynecological age was a block 1 negative predictor of the bone formation index (MoMf) (B 5 20.045 6 0.009) and explained 18.0% of the variance (P , 0.001). tably, when TT 3 was added to the model, weight was no longer a significant predictor on its own (P 5 0.0857). Fat mass (block 2 predictor) did not emerge in the multivariable models as a significant predictor of the bone formation index.
The following variables were tested in the model for the bone resorption index: block 1, gynecological age; block 2, TT 3 (no body composition variables were deemed eligible for model entry). Gynecological age was a block 1 negative predictor of the bone resorption index (B 5 20.044 6 0.009) and explained 17.3% of the variance (P , 0.001). TT 3 concentration was a block 2 positive predictor (B 5 0.004 6 0.002), and gynecological age and TT 3 concentration together explained 20.2% of the variance in the bone resorption index (P , 0.001) (unadjusted R 2 change 5 3.7%). Because the correlation analysis determined that only BMI was associated with bone balance, only simple linear regression was performed. BMI was a positive predictor of bone balance (B 5 0.036 6 0.017), although it only explained 3.1% of the variance in bone balance (P 5 0.036). There was a main effect of energy on bone resorption index, such that women in the EnD group had a lower bone resorption index than did women in the EnR group. There was a significant interaction effect of energy and estrogen status affecting the bone formation index and BTR, such that among women who were E 2 D, those who were also EnD had a lower bone formation index and lower BTR compared with those who were EnR. Bold indicates P , 0.05.
Abbreviation: BB, bone balance.
The following variables were tested in the model for BTR: block 1, gynecological age; block 2, fat mass; block 3, TT 3 . Gynecological age was a block 1 negative predictor of BTR (B 5 20.064 6 0.011) and explained 23.1% of the variance (P , 0.001). TT 3 concentration was a block 3 positive predictor (B 5 0.007 6 0.002) of BTR. Taken together, gynecological age (B 5 20.061 6 0.011) and TT 3 concentration explained 28.8% of the variance in BTR (P , 0.001) (unadjusted R 2 change 5 6.3%). Fat mass (block 2 predictor) did not emerge in the multivariable models as a significant predictor of the BTR.
Discussion
This study is, to our knowledge, the first to unravel the unique and combined contributions of energy vs estrogen status to bone turnover dynamics, namely the balance of bone formation and resorption and BTR, using bone remodeling algorithms in young, exercising women with a range of menstrual function. The most important findings of this study implicate energy as a key mediator of bone metabolism in exercising women with estrogen suppression and menstrual disturbances. Specifically, among the women who were E 2 D (presenting with oligoamenorrhea), those who were EnD (i.e., presenting with low TT 3 ) had a decreased bone formation index and a lower rate of bone turnover compared with those who were EnR (i.e., EnD 1 E 2 D vs EnR 1 E 2 D). Furthermore, EnD women had a lower index of bone resorption than did EnR women, highlighting the important role that energy plays in driving all bone turnover. Taken together, the main effect of energy on bone resorption and the interaction effect of energy and estrogen on bone formation and turnover rate suggest that when energy deficiency is present in the face of estrogen deficiency, the effects on bone turnover dynamics are amplified. By assessing not only absolute concentrations of bone formation and resorption markers (P1NP and sCTx), but also the relationship between bone formation and resorption to reflect bone balance and BTR, the findings of this study highlight additional bone metabolic characteristics that may contribute to changes in BMD and fracture risk and thus contribute to an increased understanding of how altered bone metabolism may be detrimental to overall bone health in women with the Triad.
The findings of the current study build on previously published bone turnover data from our laboratory, as De Souza et al. (14) reported an interaction effect of energy and estrogen status on bone formation, whereby P1NP was significantly lower in the women who were both EnD and E 2 D compared with all other energy and estrogen subgroups. Suppression of bone metabolism in response to energy deficiency aligns with the findings of Ihle and Loucks (10) , who reported that 5 days of exercise coupled with food restriction resulting in low EA significantly decreased bone formation (osteocalcin and P1NP) during mild to severe low EA (10, 20 A notable difference between the current study and that of Ihle and Loucks was the bone resorption finding: the current study revealed decreased, rather than increased, bone resorption in EnD compared with EnR women. We hypothesize that the lower bone resorption index in EnD women is actually an indication of overall less bone turnover due to low EA, which is supported by the finding of a lower bone formation index and BTR in the EnD 1 E 2 D women. Furthermore, the study by Ihle and Loucks (10) demonstrated the acute effects of energy deficiency as opposed to potential chronic energy deficiency experienced by the exercising women in the current study. Therefore, whereas the study by Ihle and Loucks highlighted the direct influence of energy status on bone turnover independent of any changes in menstrual function, the current study expands these findings to examine the effects of chronic energy deficiency and resultant menstrual dysfunction on the dynamics of bone turnover.
The physiological underpinnings of the findings of the current study are explained by the classic work by Wade and Schneider (37) : in the face of decreased availability of oxidizable metabolic fuels, adaptations occur to shunt the remaining available energy away from nonvital functions, such as reproduction and growth, to prioritize vital survival functions, such as thermoregulation, cellular respiration, and locomotion. The hormonal pathways connecting low EA with a suppression in growth and, specific to this study, decreased bone turnover, likely involve TT 3 , assessed in the current study as a marker of energy deficiency, and the growth hormone-IGF axis. In the absence of adequate energy, TT 3 concentrations are reduced (23) . TT 3 has been shown to directly increase IGF-1 binding in human osteoblastic (i.e., bone-forming) cells and promote IGF-1-induced osteoblast proliferation (38) . Indeed, in conjunction with reduced TT 3 , Ihle and Loucks (10) reported suppressed IGF-1 concentrations concomitant with unfavorable shifts in bone turnover toward net resorption in response to low EA. In a recent series of experiments conducted by Papageorgiou et al. (13) , acute low EA (15 kcal/kg LBM/d) induced through dietary restriction for 3 days resulted in significant decreases in bone formation measured by P1NP with simultaneous reductions in IGF-1 and TT 3 (13) , further emphasizing the association between bone formation and metabolic indicators of energy status. The current study confirms and extends these findings to a free-living environment, demonstrating Only variables that displayed a significant (P , 0.05) correlation or trend toward a significant (P , 0.10) correlation with bone turnover dynamics are displayed. Rthat energy deficiency, likely achieved by chronic underconsumption of food relative to total daily energy expenditure, suppresses bone metabolism. The use of mathematical models of bone turnover to assess the net balance of bone formation and resorption and the rate of bone turnover in premenopausal, exercising women is a novel innovation in this study. Markers of bone formation and resorption are typically measured in different units and are expected to be present in different orders of magnitude, precluding direct comparisons with one another. For instance, a "normal" measurement for P1NP is 60 ng/mL, whereas a "normal" measurement for sCTx is 0.60 ng/mL; the degree of bone formation relative to bone resorption cannot be assessed by simply comparing the concentrations of the two markers. Bone turnover algorithms, such as the MoMs and bone turnover plot approach used in the current study, remove the units of the measurement, standardize the magnitude of values the measurements can take on, and allow for a more direct and complete characterization of bone turnover. This is demonstrated in the current study. When comparing absolute bone turnover marker concentrations in the two "extreme" groups (EnD 1 E 2 D vs EnR 1 E 2 R), it was observed that bone formation and resorption markers were both suppressed in the EnD 1 E 2 D group (P1NP 5 53.6 6 3.1 mg/L, sCTx 5 0.64 6 0.05 ng/mL) compared with the EnR 1 E 2 R group (P1NP 5 65.8 6 3.3 mg/L, sCTx 5 0.71 6 0.05 ng/mL). What is not gleaned from the comparison of these absolute bone marker concentrations is whether bone formation or resorption was dominating in either group. Only by using the algorithms does it become apparent that although both groups present with net bone formation, bone balance in the EnD 1 E 2 D group (1.09 6 0.07) is lower than in the EnR 1 E 2 R group (1.19 6 0.07), and thus the En 1 E 2 D women are expected to accrue bone to a lesser extent than the EnR 1 E 2 R women.
To date, the overall implication of BTR on changes in BMD and fracture risk in premenopausal exercising women is unknown and requires future research. In postmenopausal women undergoing teriparatide treatment of osteoporosis, a positive correlation was observed between BTR and the rate of change in lumbar spine and hip BMD during a 48-week observation period (17) , suggesting that more bone turnover may result in greater BMD gains (although causation cannot be confirmed with the reported correlation analysis). Interestingly, no such correlation was noted between bone balance and the rate of change in BMD (17) . It remains to be determined whether a similar relationship is observed in younger women and whether there is any implication for fracture risk. However, note that in premenopausal exercising women, stress fractures are of more immediate concern than fragility fractures, which are observed in postmenopausal women, and therefore the relationship between bone turnover and fracture risk may differ in younger vs older populations.
The conclusions that can be drawn from this study are restricted by limitations of the investigation. First, this is a cross-sectional study, so the relationships between energy, estrogen, and bone turnover dynamics presented herein may change longitudinally; that is, changing energy or estrogen status may not change bone turnover as predicted by the cross-sectional associations. Future studies examining these temporal relationships during interventions that may alter energy, estrogen, and/or bone . Unstandardized B is displayed as mean 6 SEM. Gynecological age is age 2 age of menarche (y). Gynecological age was a negative predictor of the bone formation index, bone resorption index, and BTR. Weight was a positive predictor of the bone formation index. BMI was a positive predictor of bone balance. TT 3 concentration was a positive predictor of the bone formation index, bone resorption index, and BTR (P , 0.05).
Abbreviation: Gyn age, gynecological age. doi: 10.1210/jc.2019-00089 https://academic.oup.com/jcem 3143 turnover are warranted. Additionally, future studies assessing how BMD changes in response to changes in bone turnover dynamics across time are warranted to assess whether bone turnover algorithms and plots are viable strategies to monitor patients over time and predict BMD outcomes. A second limitation is that bone turnover dynamics are expected to change with age and, therefore, the results presented should not be generalized to all populations. Rather, the results are pertinent to exercising young women, age 18 to 35 years. Lastly, the study is limited by absence of a validation of the MoM scores and bone turnover plot methodology to accurately capture bone balance and BTR in premenopausal exercising women. The current analysis is based on the assumption that the women in the in-house reference database of exercising, ovulatory, eumenorrheic women exhibit balanced bone formation and resorption, such that comparisons to this reference group will represent deviations from the norm. Longitudinal studies are required to demonstrate that bone balance results in the maintenance of BMD across time, thus validating the use of the reference group as a norm. Validation studies could additionally make use of isotopic tracer kinetics (e.g., calcium tracers) to identify whether bone balance or BTR are confirmed by the isotopic balance dynamics.
Conclusions
Using bone turnover algorithms, this study demonstrated that energy status in exercising women plays an important role in orchestrating bone turnover, impacting bone formation, resorption, and the rate of turnover. Compared with assessing bone formation and resorption markers in isolation, the technique of assessing bone formation and resorption relative to one another allows for a more comprehensive characterization of bone metabolism in exercising women in relationship to energy and estrogen status, and improves our understandings of bone physiology in the face of the Triad. Bone turnover was especially influenced by energy status among exercising women who are E 2 D, suggesting that in exercising women with menstrual disturbances, correcting an energy deficiency is particularly important to protect bone health. Furthermore, the findings were derived from a sample of women representing a wide range of exercise volumes (120 to 10001 minutes per week), suggesting that the demonstrated relationships between energy, estrogen, and bone health pertain not only to competitive athletes or highly active women, but also those who are recreationally active or exercise at lower volumes. Clinically, the importance of energy status as a mediator of bone health in young women cannot be overstated. In young, exercising women with irregular or absent menstrual cycles, it appears that estrogen deficiency, although detrimental in part, is not the key threat to bone health. Rather, poor nutrition and inadequate caloric intake to support the energetic needs of exercise in addition to daily living have a direct impact on bone metabolism that may result in decreased BMD or not achieving optimal peak bone mass. Menstrual disturbances are a manifestation of energy deficiency that may amplify the detrimental effects of low EA on bone. Owing to the suppression of ovarian steroids that accompanies menstrual disturbances, clinicians may be tempted to prescribe exogenous estrogen therapy in the form of combined hormonal contraception (i.e., birth control pills) to address estrogen deficiency in amenorrheic women; however, the Female Athlete Triad Coalition promotes the evidencebased recommendation that nutritional therapy, which results in improved energy status and, often, weight and fat gain and menstrual resumption, ought to be the first line of treatment of female athletes with menstrual disturbances of organic cause (39, 40) . The current study affirms the importance of nutrition, establishing that energy status strongly influences bone metabolism, regardless of estrogen status, but especially in the face of estrogen deficiency.
